Robert W. Baird Analysts Give Amicus Therapeutics (FOLD) a $20.00 Price Target

Amicus Therapeutics (NASDAQ:FOLD) has been assigned a $20.00 price objective by stock analysts at Robert W. Baird in a report issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Robert W. Baird’s target price indicates a potential upside of 34.45% from the stock’s current price.

FOLD has been the topic of several other reports. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, January 15th. Cowen reissued a “buy” rating and set a $22.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $19.06.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded down $2.00 during trading hours on Wednesday, reaching $14.88. 5,666,313 shares of the company’s stock traded hands, compared to its average volume of 2,950,000. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a 52 week low of $5.82 and a 52 week high of $17.40. The firm has a market cap of $2,470.00, a P/E ratio of -8.13 and a beta of 1.45.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. During the same period last year, the firm earned ($0.33) earnings per share. Amicus Therapeutics’s revenue for the quarter was up 419.0% compared to the same quarter last year. analysts expect that Amicus Therapeutics will post -1.52 EPS for the current year.

In other news, CEO John F. Crowley sold 5,920 shares of the business’s stock in a transaction on Saturday, December 29th. The shares were sold at an average price of $14.75, for a total transaction of $87,320.00. Following the transaction, the chief executive officer now directly owns 341,051 shares in the company, valued at approximately $5,030,502.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the transaction, the insider now owns 69,184 shares in the company, valued at $940,210.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 250,390 shares of company stock worth $3,620,581. 3.40% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of FOLD. Schwab Charles Investment Management Inc. grew its holdings in shares of Amicus Therapeutics by 5.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 592,934 shares of the biopharmaceutical company’s stock valued at $5,971,000 after acquiring an additional 29,983 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Amicus Therapeutics by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock valued at $2,073,000 after acquiring an additional 28,800 shares in the last quarter. Teachers Advisors LLC grew its holdings in shares of Amicus Therapeutics by 3.2% during the 2nd quarter. Teachers Advisors LLC now owns 261,545 shares of the biopharmaceutical company’s stock valued at $2,634,000 after acquiring an additional 8,046 shares in the last quarter. TIAA CREF Investment Management LLC grew its holdings in shares of Amicus Therapeutics by 12.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 487,751 shares of the biopharmaceutical company’s stock valued at $4,912,000 after acquiring an additional 52,136 shares in the last quarter. Finally, Nationwide Fund Advisors grew its holdings in shares of Amicus Therapeutics by 27.9% during the 2nd quarter. Nationwide Fund Advisors now owns 168,709 shares of the biopharmaceutical company’s stock valued at $1,699,000 after acquiring an additional 36,764 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Robert W. Baird Analysts Give Amicus Therapeutics (FOLD) a $20.00 Price Target” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/08/robert-w-baird-analysts-give-amicus-therapeutics-fold-a-20-00-price-target.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply